Eli Lilly Is The Nvidia Of Weight Loss And GLP-1 Space, Says Roundhill Investments CEO, Emphasizes Market Leadership And Growth Potential Of Zepbound Maker
Gilead Sciences Trades in the Green for Seventh Straight Session
Moderna Unusual Options Activity
Decoding Gilead Sciences's Options Activity: What's the Big Picture?
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Evaluating Regeneron Pharmaceuticals Against Peers In Biotechnology Industry
Exchange-Traded Funds Edge Lower, Equity Futures Mixed Pre-Bell Tuesday as Stocks Struggle for Direction
Ready for Fed Rate Cuts? Biotech's Potential to Watch
$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today
Sector Update: Health Care Stocks Higher Pre-Bell Monday
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Monday as Middle East Tensions Hold Back Markets
Is the rebound fading? Goldman Sachs: Hedge funds are selling stocks at the fastest pace in more than two years.
In August, 'smart money' is selling global equities at the fastest pace since March 2022, with the most net selling in North America. Hedge funds are skeptical of the sustainability of the stock market rebound, and geopolitical concerns continue to be worrying. The 'fly' of the economic situation may soon hit the glass windshield.
Regeneron Highlights Scientific Innovation And Leadership In Respiratory Disease Management At ERS 2024, Featuring Dupixent And Itepekimab
Eli Lilly, Novo Nordisk to Maintain 'Two Horse Race' in GLP-1 Weight Loss Market
Stocks Most Loved and Shunned by Hedge and Mutual Funds
Snowflake, JD.com And Temu Parent PDD Are Among Top 8 Large Cap Losers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio?
Eli Lilly Alzheimer's Drug Set to Face Same Fate as Biogen's in U.K.: Report
$100 Invested In This Stock 5 Years Ago Would Be Worth $500 Today
Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals
U.S. to Restart Free COVID Test Program as Cases Spike